The consulting services (“the Services”) include:

1. Proposed new vaccine production facility pre-feasibility study.

a. The Firm is to conduct a pre-feasibility study for the type of facility agreed upon in Phase 1. The study should identify enablers and barriers for the new facility to be able to operate in a sustainable manner.

b. The Firm must then recommend potential solutions for these gaps, especially ones which can be effectively implemented by governments or through government support and evaluate the feasibility the proposed solutions can be implemented successfully1 . A recommendation on where the facility should be located must also be made if a location wasn’t already agreed as part of Phase 1

c. The Firm must deliver a high level production facility business case which covers the following: Estimated capital expense (CAPEX), operational expense (OPEX) and Cost of Goods (COGs) for the products to be made there, an explanation of the scope of the facility (capacity during pandemic and non-pandemic times, production steps and technologies to be employed), timeline for facility build and licensure and finally the economies of scale and internal operational considerations (facility utilization, product portfolio, etc) needed for the facility to be viable in both pandemic and nonpandemic times. A preliminary financial model including CAPEX, OPEX and COGs estimates should be created to detail the overall financial viability of the facility over the initial 5-10 years of operation.

d. The Firm will participate in a series of meetings to keep the Steering Committee and Member States abreast of the findings of the pre-feasibility study as it is being conducted

2. Co-develop, facilitate, and actively participate in workshops to define a strategic roadmap for implementing new vaccine manufacturing facility.

a. A workshop will be held where the final recommended concept package for the new vaccine facility will be presented by the Firm to Member States for validation2 . If the outcome of the pre-feasibility study is positive, the concept package will serve as the foundation of what will be used to engage potential financiers, technology transfer partners, facility design firms and other firms required for the project.

b. The Firm will create a roadmap for the implementation of the approved facility concept package. The roadmap shall layout the steps required to progress from the end of the pre-feasibility study through to final facility project execution. It must also include a list of roles and responsibilities for the entities required to progress through this roadmap. A final workshop will be held for Member States to review and validate the roadmap.

3. Co-develop, facilitate, and actively participate in a public/private forum to socialize the results of pre-feasibility and discuss the roadmap

a. Firm(s) shall present an overview of the roadmap and pre-feasibility and how they lead to the final recommendations which were approved by Member States.

b. Forum attendees to provide feedback, pressure test the concepts and express willingness or ability to participate in such a cooperative agreement

c. Forum attendees to include but are not limited to: representatives from Member States, the Bank, global health organizations (i.e., PAHO, WHO, CEPI, COVAX), local vaccine and pharmaceutical manufacturers and other actors in the local vaccine supply chain.